Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 31.68
(1.57%)
USD 31.68
(1.57%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 529.01 Million USD | -20.38% |
| 2022 | 534.4 Million USD | 25.68% |
| 2021 | 425.21 Million USD | 45.45% |
| 2020 | 292.34 Million USD | 28.49% |
| 2019 | 227.52 Million USD | -8.66% |
| 2018 | 249.09 Million USD | 32.86% |
| 2017 | 187.48 Million USD | 26.0% |
| 2016 | 148.8 Million USD | 25.74% |
| 2015 | 118.33 Million USD | 28.55% |
| 2014 | 92.05 Million USD | 26.39% |
| 2013 | 72.83 Million USD | 66.87% |
| 2012 | 43.64 Million USD | 13.21% |
| 2011 | 38.55 Million USD | -4.16% |
| 2010 | 40.22 Million USD | 18.64% |
| 2009 | 33.9 Million USD | -2.42% |
| 2008 | 34.75 Million USD | 49.27% |
| 2007 | 23.28 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 98.78 Million USD | 5.18% |
| 2024 Q2 | 111.48 Million USD | 0.59% |
| 2024 Q1 | 110.83 Million USD | 6.55% |
| 2023 Q4 | 104.02 Million USD | -17.83% |
| 2023 Q3 | 126.59 Million USD | -3.56% |
| 2023 Q1 | 126.77 Million USD | 12.75% |
| 2023 Q2 | 131.26 Million USD | 3.54% |
| 2023 FY | 425.48 Million USD | -20.38% |
| 2022 FY | 534.4 Million USD | 25.68% |
| 2022 Q4 | 112.44 Million USD | -26.27% |
| 2022 Q2 | 137.5 Million USD | 4.22% |
| 2022 Q1 | 131.94 Million USD | -2.15% |
| 2022 Q3 | 152.51 Million USD | 10.91% |
| 2021 Q3 | 97.69 Million USD | 7.43% |
| 2021 Q1 | 101.74 Million USD | 26.66% |
| 2021 FY | 425.21 Million USD | 45.45% |
| 2021 Q2 | 90.93 Million USD | -10.62% |
| 2021 Q4 | 134.83 Million USD | 38.02% |
| 2020 Q3 | 77.6 Million USD | 6.61% |
| 2020 Q2 | 72.79 Million USD | 17.77% |
| 2020 Q1 | 61.81 Million USD | 11.34% |
| 2020 FY | 292.34 Million USD | 28.49% |
| 2020 Q4 | 80.32 Million USD | 3.5% |
| 2019 Q1 | 56.36 Million USD | -21.6% |
| 2019 Q3 | 57.59 Million USD | -0.79% |
| 2019 Q2 | 58.05 Million USD | 3.0% |
| 2019 Q4 | 55.51 Million USD | -3.6% |
| 2019 FY | 227.52 Million USD | -8.66% |
| 2018 FY | 249.09 Million USD | 32.86% |
| 2018 Q1 | 55.75 Million USD | 11.65% |
| 2018 Q2 | 60.13 Million USD | 7.85% |
| 2018 Q3 | 61.31 Million USD | 1.96% |
| 2018 Q4 | 71.89 Million USD | 17.25% |
| 2017 Q1 | 37.83 Million USD | -10.56% |
| 2017 Q3 | 53.8 Million USD | 17.22% |
| 2017 Q4 | 49.93 Million USD | -7.19% |
| 2017 FY | 187.48 Million USD | 26.0% |
| 2017 Q2 | 45.9 Million USD | 21.31% |
| 2016 Q3 | 33.54 Million USD | -9.9% |
| 2016 Q2 | 37.23 Million USD | 4.22% |
| 2016 Q1 | 35.72 Million USD | 8.21% |
| 2016 FY | 148.8 Million USD | 25.74% |
| 2016 Q4 | 42.3 Million USD | 26.13% |
| 2015 Q2 | 30.21 Million USD | 30.88% |
| 2015 Q3 | 32.02 Million USD | 6.01% |
| 2015 Q4 | 33.01 Million USD | 3.07% |
| 2015 FY | 118.33 Million USD | 28.55% |
| 2015 Q1 | 23.08 Million USD | -2.96% |
| 2014 Q4 | 23.79 Million USD | 8.14% |
| 2014 Q3 | 22 Million USD | -9.31% |
| 2014 Q2 | 24.25 Million USD | 10.22% |
| 2014 FY | 92.05 Million USD | 26.39% |
| 2014 Q1 | 22 Million USD | 6.71% |
| 2013 Q1 | 18.05 Million USD | 30.51% |
| 2013 Q3 | 18.39 Million USD | 16.77% |
| 2013 Q4 | 20.62 Million USD | 12.1% |
| 2013 FY | 72.83 Million USD | 66.87% |
| 2013 Q2 | 15.75 Million USD | -12.73% |
| 2012 Q2 | 9.34 Million USD | 15.61% |
| 2012 Q4 | 13.83 Million USD | 11.74% |
| 2012 FY | 43.64 Million USD | 13.21% |
| 2012 Q3 | 12.38 Million USD | 32.45% |
| 2012 Q1 | 8.08 Million USD | -21.38% |
| 2011 Q3 | 9.92 Million USD | 8.53% |
| 2011 Q4 | 10.28 Million USD | 3.62% |
| 2011 FY | 38.55 Million USD | -4.16% |
| 2011 Q2 | 9.14 Million USD | -0.57% |
| 2011 Q1 | 9.19 Million USD | -14.52% |
| 2010 FY | 40.22 Million USD | 18.64% |
| 2010 Q4 | 10.76 Million USD | 0.0% |
| 2009 FY | 33.9 Million USD | -2.42% |
| 2009 Q4 | 8.6 Million USD | 0.0% |
| 2008 FY | 34.75 Million USD | 49.27% |
| 2007 FY | 23.28 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 94.841% |
| Dynavax Technologies Corporation | 219.14 Million USD | -141.398% |
| Illumina, Inc. | 3.81 Billion USD | 86.126% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 74.232% |
| Biogen Inc. | 5.2 Billion USD | 89.836% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -17.299% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 51.44% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 61.125% |
| Waters Corporation | 943.51 Million USD | 43.932% |
| Perrigo Company plc | 1.52 Billion USD | 65.39% |
| uniQure N.V. | 285.08 Million USD | -85.562% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -29.404% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -23.702% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -91.884% |
| bluebird bio, Inc. | 240.23 Million USD | -120.208% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -271.332% |
| Imunon, Inc. | 21.03 Million USD | -2415.455% |
| Myriad Genetics, Inc. | 600.1 Million USD | 11.846% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 66.864% |
| Nektar Therapeutics | 190.9 Million USD | -177.11% |
| Editas Medicine, Inc. | 247.3 Million USD | -113.911% |
| Verastem, Inc. | 92.08 Million USD | -474.487% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.697% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -3703.197% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -338.442% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1084.344% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 69.706% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -131.332% |
| Evolus, Inc. | 189.75 Million USD | -178.78% |
| Adicet Bio, Inc. | 152.03 Million USD | -247.947% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -4257.228% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 81.209% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -94.563% |
| FibroGen, Inc. | 398.11 Million USD | -32.88% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 74.988% |
| OPKO Health, Inc. | 574.68 Million USD | 7.948% |
| Homology Medicines, Inc. | 9.87 Million USD | -5257.073% |
| Geron Corporation | 70.44 Million USD | -650.999% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 70.611% |
| Exelixis, Inc. | 1.58 Billion USD | 66.661% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -424.672% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -848.797% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 4.089% |
| Zoetis Inc. | 2.76 Billion USD | 80.868% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -11.053% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -990.699% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 88.921% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1251.138% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 32.142% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -43.514% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -76.739% |
| Blueprint Medicines Corporation | 722.86 Million USD | 26.817% |
| Insmed Incorporated | 949.26 Million USD | 44.271% |
| TG Therapeutics, Inc. | 198.47 Million USD | -166.538% |
| Incyte Corporation | 1.19 Billion USD | 55.564% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 49.328% |